EP4720079A1 - Für mitochondrien spezifische transkriptionsinhibitoren - Google Patents

Für mitochondrien spezifische transkriptionsinhibitoren

Info

Publication number
EP4720079A1
EP4720079A1 EP24814717.5A EP24814717A EP4720079A1 EP 4720079 A1 EP4720079 A1 EP 4720079A1 EP 24814717 A EP24814717 A EP 24814717A EP 4720079 A1 EP4720079 A1 EP 4720079A1
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
compound
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24814717.5A
Other languages
English (en)
French (fr)
Inventor
Michael P. Lisanti
Federica Sotgia
Filippo DI PISA
Jussi Kangasmetsa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunella Biotech Inc
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of EP4720079A1 publication Critical patent/EP4720079A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24814717.5A 2023-05-26 2024-05-26 Für mitochondrien spezifische transkriptionsinhibitoren Pending EP4720079A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363469115P 2023-05-26 2023-05-26
PCT/IB2024/055121 WO2024246717A1 (en) 2023-05-26 2024-05-26 Mitochondria specific transcription inhibitors

Publications (1)

Publication Number Publication Date
EP4720079A1 true EP4720079A1 (de) 2026-04-08

Family

ID=93656839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24814717.5A Pending EP4720079A1 (de) 2023-05-26 2024-05-26 Für mitochondrien spezifische transkriptionsinhibitoren

Country Status (7)

Country Link
EP (1) EP4720079A1 (de)
KR (1) KR20260018060A (de)
CN (1) CN121194981A (de)
AU (1) AU2024278807A1 (de)
IL (1) IL324610A (de)
MX (1) MX2025013580A (de)
WO (1) WO2024246717A1 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102009560B1 (ko) * 2017-07-12 2019-08-09 고려대학교 산학협력단 저산소환경에 의해 활성화되고 미토콘드리아에 대한 특이적 표적화가 가능한 항암 치료진단제

Also Published As

Publication number Publication date
WO2024246717A1 (en) 2024-12-05
CN121194981A (zh) 2025-12-23
MX2025013580A (es) 2025-12-01
KR20260018060A (ko) 2026-02-06
IL324610A (en) 2026-01-01
AU2024278807A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
CN102389409B (zh) Trp-p8活性化合物和治病性治疗方法
US20130281396A1 (en) Treatment of diseases by epigenetic regulation
EP2061452B1 (de) Verwendung von kaffeesäure und ihren derivaten gegen krebs
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
TW201609094A (zh) 治療癌症之新穎方法
JP6863742B2 (ja) 新規アントラニルアミドとその使用
JP7069031B2 (ja) 増殖性疾病の組み合せ療法
CN103864764A (zh) 吲唑取代的嘧啶胺衍生物、其制备方法和用途
AU2024278807A1 (en) Mitochondria specific transcription inhibitors
CN112513000B (zh) 新型联苯衍生物化合物及其用途
US20190002411A1 (en) 13-Cis-RAMBA RETINAMIDES THAT DEGRADE MNKs FOR TREATING CANCER
AU2024257603A1 (en) Treatment of cancer with a met kinase inhibitor
US20250206713A1 (en) 2-[(2-oxo-4-phenyl-2h-chromen-7-yl)oxy] propanamido derivatives
KR102698500B1 (ko) Axl 억제제로 사용하기 위한 피리도피리미디논 유도체
WO2022164901A1 (en) Enhanced anti-proliferative and antitumor immune effects of mitochondria-targeted hydroxyurea
CN102311438A (zh) 喹唑啉化合物
AU2024290511A1 (en) Mitochondria specific transcription inhibitor compounds
CN108456184B (zh) 一种靶向egfr与eps8结合的小分子抑制剂及其应用
WO2016079067A1 (en) Compounds targeting the bfl-1 anti-apoptotic protein and uses thereof for the treatment of cancer
US20260034115A1 (en) Yap1 inhibitors
WO2014000686A1 (zh) 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用
US20240109852A1 (en) Ferroptosis-HDAC Inhibitor Hybrid Anticancer Agents
US20250115593A1 (en) Rocaglate derivatives and uses thereof
US10058618B2 (en) PAK1-blocking 1,2,3-triazolyl esters
US20170022215A1 (en) Compounds for Eradicating or Inhibiting Proliferation of Cancer Stem Cells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR